Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Announces Revisions to Conditional Approval Rules
October 25, 2024
- MHLW Outlines Envisaged Cases of Regulatory Submissions without Japanese Data, Covering Rare Disease Drugs
October 24, 2024
- Contribution to Drug Discovery Up for Discussion in Revising Core Hospital Criteria
October 24, 2024
- Marukawa Touts Importance of Drug Innovation in Lower House Campaign
October 24, 2024
- LDP’s Hashimoto Makes Rare Speech on Drug Prices amid Close Race in Okayama
October 22, 2024
- Ex-Health Minister Gets Kostaive Shot, Warns against “Unscientific Concerns”
October 21, 2024
- ITP Pediatric Dosage Approvals on Agenda of MHLW Panel for Oct. 31
October 18, 2024
- MHLW Panel to Review BeiGene’s 1st Drug Candidate in Japan and More on Oct. 30
October 17, 2024
- Multiple Candidates Tout Drug Policies as Snap Poll Campaigning Starts
October 16, 2024
- MHLW to Run Follow-Up Survey on Updated Commercial Guidelines, Solo Distribution
October 15, 2024
- Japan Political Parties Push Varied Pharma Policies as Election Campaign Kicks Off
October 15, 2024
- Japan’s Healthcare Spending Hits 46.7 Trillion Yen in FY2022
October 15, 2024
- MHLW Asks for Ramp Up of HPV Vaccines after 5-Fold Rise in Demand
October 11, 2024
- MHLW Orders Label Revision for Systemic NSAIDs
October 11, 2024
- Xocova to Face CEA Price Cuts on Poor Cost Performance vs. SOC
October 10, 2024
- Kisunla to Follow Same Rules as Leqembi in Pricing and Post-Launch Review
October 10, 2024
- Supply of Anapeine Generic to Start by Year-End: Minister
October 9, 2024
- MHLW Issues Notification to Spur Use of RWD in Place of Clinical Trial Data
October 7, 2024
- New Health Minister to Stick to Honebuto Text on Off-Year Plan
October 7, 2024
- Ishiba Makes No Mention on Pharma in First Policy Speech
October 7, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…